GLP's Therapy in Adolescents: What Prescribers Need to Know
GLP's receptor agonists are increasingly being studied and used in adolescents with obesity. Here is what the evidence shows and the regulatory and ethical considerations for prescribers.
GLP-1 Therapy in Adolescents: What Prescribers Need to Know
Adolescent obesity is a significant and growing public health problem. GLP-1 receptor agonists, which have transformed adult obesity treatment, are increasingly being studied and used in adolescent patients. For prescribers who see adolescent patients, understanding the evidence, the regulatory landscape, and the ethical considerations is essential.
The Adolescent Obesity Problem
Approximately 20% of children and adolescents in the United States are obese. Adolescent obesity is associated with:
- Type 2 diabetes
- Hypertension
- Dyslipidemia
- Sleep apnea
- Non-alcoholic fatty liver disease
- Psychological consequences (depression, anxiety, social isolation)
- Persistence into adulthood (approximately 80% of obese adolescents become obese adults)
Traditional interventions — lifestyle modification, behavioral therapy — have limited long-term efficacy in adolescents. This has driven interest in pharmacological approaches.
FDA-Approved GLP-1 Therapies for Adolescents
Semaglutide (Wegovy)
The FDA approved semaglutide (Wegovy) for adolescents aged 12 and older with obesity (BMI ≥95th percentile for age and sex) in December 2022.
Evidence: The STEP TEENS trial enrolled 201 adolescents aged 12–17 with obesity. At 68 weeks, semaglutide produced an average weight reduction of 16.1% compared to 0.6% with placebo. Improvements in cardiometabolic risk factors were also observed.
Dosing: Same titration schedule as adults, targeting 2.4 mg weekly.
Safety: The safety profile in adolescents was similar to adults, with GI side effects being the most common adverse events.
Liraglutide (Saxenda)
The FDA approved liraglutide (Saxenda) for adolescents aged 12 and older with obesity in 2020.
Evidence: A randomized trial showed liraglutide produced greater weight loss than placebo in adolescents, though the effect size was smaller than that seen with semaglutide.
Tirzepatide in Adolescents
Tirzepatide is not yet FDA-approved for adolescents, but Eli Lilly's Phase 3 TRIUMPH program includes a pediatric trial (TRIUMPH-4). Results are expected in 2026–2027.
Compounded GLP-1s in Adolescents
For adolescents who cannot access branded GLP-1 therapies (due to cost, insurance, or supply), compounded GLP-1s represent an access pathway. Key considerations:
Prescribing authority: The prescribing provider must have appropriate authority to prescribe for adolescent patients. Pediatric prescribing may require specific training or credentials depending on the state.
Parental consent: For patients under 18, parental or guardian consent is required for treatment.
Dosing: Adolescent dosing follows the same titration schedule as adults, but some prescribers use more conservative titration given the younger patient population.
Monitoring: More frequent monitoring may be appropriate for adolescent patients.
Ethical Considerations
GLP-1 therapy in adolescents raises several ethical considerations that prescribers should think through:
Body image: Adolescence is a critical period for body image development. GLP-1 therapy should be part of a comprehensive approach that includes psychological support and healthy body image messaging.
Long-term safety: The long-term safety of GLP-1 therapy in adolescents is not fully established. The medications have been studied for 1–2 years in adolescents, but the effects of decades of use starting in adolescence are unknown.
Dependency: As with adults, most adolescents will regain weight if GLP-1 therapy is stopped. Prescribers should discuss the long-term nature of treatment with patients and families.
Lifestyle foundation: GLP-1 therapy should be combined with lifestyle interventions — not used as a substitute for them.
Practical Prescribing Considerations
Patient selection: GLP-1 therapy is appropriate for adolescents with obesity (BMI ≥95th percentile) who have not achieved adequate response to lifestyle interventions.
Multidisciplinary approach: Adolescent obesity treatment is most effective when it involves a multidisciplinary team — prescriber, dietitian, behavioral health provider, and family.
Family involvement: Adolescent patients need family support for successful GLP-1 therapy. Involve parents or guardians in the treatment plan.
School and social considerations: Adolescents may face social challenges related to their weight loss treatment. Discuss these with patients and families.
This content is for informational and educational purposes only. It does not constitute medical advice. Prescribers should review current prescribing information and use clinical judgment when treating adolescent patients.
Explore Topics
Written by
MedClinic Partners Editorial Team
B2B Medical Supply & Compounding Experts
The MedClinic Partners editorial team is composed of licensed medical operators, compounding compliance specialists, and mass-tort attorneys with direct experience running GLP-1 and peptide programs across all 50 states. Every article is reviewed for clinical accuracy, regulatory compliance, and practical applicability before publication.
Editorial standards: All content on medclinicpartners.com is reviewed by licensed medical operators and compounding compliance specialists before publication. Articles are updated when regulatory guidance changes. This content is for licensed healthcare providers only and does not constitute medical advice.
